- Home
- CLLS vs VSTM Comparison
CLLS vs VSTM Comparison
Compare CLLS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | VSTM |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | 102 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 395.4M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CLLS | VSTM |
|---|---|---|
| Price | $3.35 | $4.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.33 | ★ $16.50 |
| AVG Volume (30 Days) | 36.3K | ★ 2.8M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | $0.98 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $1.62 | $3.43 |
| 52 Week High | $5.48 | $11.25 |
Technical Indicators
Market Signals| Indicator | CLLS | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 55.42 | 57.96 |
| Support Level | $2.86 | $3.49 |
| Resistance Level | $3.41 | $6.67 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 86.96 | 93.86 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.